| Expression pattern: |
UP |
| Associated gene: |
HNRNPLL, MYO1B |
| Associated microRNA: |
- |
| Biological function: |
Enhances oxidative phosphorylation (OXPHOS) for adaptation to energy stress; promotes cell proliferation; enhances migration and invasion; promotes tumor growth in vivo; induces cell cycle progression and inhibits apoptosis. |
| Molecular mechanism: |
circZFR binds HNRNPLL and protects it from ubiquitination-mediated degradation, thereby modulating alternative splicing (e.g., promoting MYO1B exon 23 inclusion) and activating AKT-mTOR signaling to enhance OXPHOS. |
| Biological pathway or process: |
oxidative phosphorylation (promotes); proliferation (promotes); cell cycle (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); PI3K/AKT/mTOR (promotes); ceRNA regulation (inhibits); ubiquitination (inhibits); other pathway/process (other) |
| Detected method: |
Q
S
M
|
| Validation methods: |
Microarray; RNA-seq; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Co-IP; Luciferase Reporter Assay; Transfection; EdU Staining; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circZFR expression is associated with higher T stage and poor prognosis, and is an independent prognostic factor in LUAD. |
| Description: |
In LUAD, circZFR (hsa_circ_0072088) is induced by glucose deprivation and is upregulated in tumors. It promotes OXPHOS and malignant phenotypes by binding and stabilizing HNRNPLL (blocking ubiquitination), thereby altering alternative splicing (including MYO1B exon 23 inclusion) and activating AKT-mTOR signaling; high circZFR correlates with advanced T stage and poor prognosis. |
| Confidence score: |
0.8988 |